Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14229118 | 0.94 | L3MBTL1 (0.52) | TACR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL14230000 | 0.91 | TACR1 (0.49) | TACR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8376444 | 0.89 | TACR1 (0.49) | TACR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8014785 | 0.89 | TACR1 (0.65) | TACR1HTR1A | |
| SCHEMBL14200310 | 0.84 | TACR1 (0.44) | TACR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10990821 | 0.82 | HTR1A (0.62) | TACR1HTR1A | |
| SCHEMBL11509359 | 0.82 | TACR1 (0.58) | TACR1TDP1HTR1A | |
| SCHEMBL5369797 | 0.82 | TACR1 (0.55) | TACR1HTR1A | |
| SCHEMBL11228139 | 0.81 | TACR1 (0.40) | TACR1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL1858027 | 0.78 | HTR1A (0.67) | L3MBTL1MEN1KMT2ATDP1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5610165-A | N-acylpiperidine tachykinin antagonists | MERCK & CO., INC. (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1995022525-A1 | N-ACYLPIPERIDINE TACHYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1995-08-24 | — | — | WO | disclosed |